Evidence map›Paper›PMID 39567652›Full record

Observational studyJournal of perinatology : official journal of the California Perinatal Association2026

Salivary cortisol is not associated with dexamethasone response in preterm infants with evolving bronchopulmonary dysplasia.

Tamorah Lewis, Erik A Jensen, Sherry Courtney, Jonathan Slaughter, Matthew J Kielt, Narayan Prahbu Iyer, Cheri Gauldin, Christopher Nitkin, Hung-Wen Yeh, William Truog

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tamorah LewisDivision of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada. Tamorah.lewis@sickkids.ca.ORCID http://orcid.org/0000-0003-2137-8339
Erik A JensenDepartment of Pediatrics, Division of Neonatology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA, USA.
Sherry CourtneyDivision of Neonatology, Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Research Institute, Fayetteville, NC, USA.ORCID http://orcid.org/0000-0003-1180-6598
Jonathan SlaughterComprehensive Center for Bronchopulmonary Dysplasia, Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-6831-7520
Matthew J KieltComprehensive Center for Bronchopulmonary Dysplasia, Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-4568-9070
Narayan Prahbu IyerFetal and Neonatal Institute, Division of Neonatology, Children's Hospital Los Angeles Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3589-0018
Cheri GauldinCenter for Infant Pulmonary Disorders, Children's Mercy Hospital; and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Christopher NitkinCenter for Infant Pulmonary Disorders, Children's Mercy Hospital; and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.ORCID http://orcid.org/0000-0001-5718-4523
Hung-Wen YehDivision of Health Services and Outcomes Research, Children's Mercy Hospital; and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.ORCID http://orcid.org/0000-0002-9904-3275
William TruogCenter for Infant Pulmonary Disorders, Children's Mercy Hospital; and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.

Funding

Less Lumping, Smarter Splitting: Genomics and Metabolomics of Systemic Steroid Response in Bronchopulmonary DysplasiaR21HD101111 · NICHD · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI NITKIN, CHRISTOPHER RYAN · 2020 to 2021
$454k
NICHD NIH HHS R21 HD101111U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1R21HD101111
6 · The paper itself

Abstract

objectiveShort-term treatment efficacy of systemic dexamethasone (DEX) in preterm infants with bronchopulmonary dysplasia (BPD) is highly variable. Our objective was to assess if salivary cortisol may serve as a reliable biomarker of steroid response. STUDY

designMulti-site prospective observational cohort study. Salivary cortisol was measured before and after DEX treatment. Respiratory Severity Score (RSS) quantified clinical response.

resultsFifty-four infants with median (inter-quartile range) gestational age of 25.1 (24.1,26.5) weeks initiated DEX at 30 (23,48) days' postnatal age. Median baseline and post-treatment cortisol levels were 0.3 (0.2,0.6) μg/dl; 8.3 (5.5,16.5) nmol/L and 0.2 (0.1,0.3) μg/dl; 5.5 (2.8,8.3) nmol/L, respectively. RSS values decreased by a median of 3.1(1.6,5.0) Change in RSS did not correlate with baseline cortisol or change in cortisol levels.

conclusionIn this first study to assess salivary cortisol as a biomarker for DEX response in BPD, salivary cortisol did not predict dexamethasone response.

Indexed as

Bronchopulmonary DysplasiaDexamethasoneGlucocorticoidsHydrocortisoneSalivaBiomarkersFemaleGestational AgeHumansInfant, NewbornInfant, PrematureMaleProspective StudiesSeverity of Illness IndexTreatment OutcomeBiomarkersDexamethasoneGlucocorticoidsHydrocortisone

Identifiers

PMID39567652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.